Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Human cell surface antigen CD47 is an immunoglobulin superfamily member acting primarily through interaction with SIRPα to inhibit phagocytosis—a mechanism exploited by tumors—and serves diverse roles across immunity and metabolism with significant therapeutic interest.
Monoclonal antibodies against CD47 designed to block the CD47–SIRPα interaction, promoting tumor cell elimination
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human Cell Surface Antigen CD47 (CD47).